Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis. Mark Lebwohl, ...
At Horizons in Advanced Practice, Evangelia Nezis, NP, shares early results with oral peptides and takeaways on type 2 ...
A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...
C, shares how journal case reports led to rapid results for a patient with an uncommon skin condition. After nearly 10 years on isotretinoin with minimal improvement, Sharon Doering, PA-C, tried a ...
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
At Horizons in Advanced Practice, Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed oral and targeted psoriasis therapies and ...
Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...
Aclaris Therapeutics announced positive phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody ...
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy. The treatment landscape for psoriasis has changed ...
Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...
The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...
One of the most common misconceptions Feldman encounters among patients and caregivers is that eczema is simply a problem of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results